Peginterferon and ribavirin for hepatitis C [8]

New England Journal of Medicine

Volumn 356, Issue 12, 2007, Pages 1270-

  Salem, Chaker Ben ^a   Hmouda, Houssem ^a   Bouraoui, Kamel ^a  

^a UNIVERSITY OF SOUSSE   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

AMYLASE BLOOD LEVEL; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PANCREATITIS; PATIENT EDUCATION; PRIORITY JOURNAL; RECURRENT DISEASE; SIDE EFFECT; SUPERINFECTION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

EID: 33947508685     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Chaudhari S, Park J, Anand BS, et al. Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C. Dig Dis Sci 2004;49:1000-6.
2. Biour M, Daoud H, Salem CB. Drug-induced pancreatitis: second edition of the bibliographic database of pancreatitis related to drugs. Gastroenterol Clin Biol 2005;29:353-9. (In French.)
3. Laguno M, Milinkovic A, de Lazzari E, et al. Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. Antivir Ther 2005;10:423-9.
4. Perronne C. Antiviral hepatitis and antiretroviral drug interactions. J Hepatol 2006;44:Suppl:S119-S125.